Microdosing

How are you feeling? Perhaps the most crucial question we can ask ourselves so we might know and begin to listen to what it is that we need …

On that note, we’ve had so many questions about micro dosing that we thought we’d dedicate a post to sharing a first person experience.

We don’t currently offer a micro dosing option -our retreats are for full psychedelic mushroom experiences, but many who attend want to explore continuing their connection with the plant in this way. Read on to learn about Josh Wilson’s experience with psilocybin microdosing …

The Biden administration is preparing for legal psychedelics within two years

The Biden administration’s Department of Health and Human Services is anticipating that the FDA will approve psychedelic therapies, using MDMA and psilocybin, within two years, The Intercept reported.

The May letter — which had not been made public before — comes from the Substance Abuse and Mental Health Services Administration (SAMHSA). It was sent by Miriam Delphin-Rittmon, Assistant Secretary for Mental Health and Substance Use, to Representative Madeleine Dean of Pennsylvania. 

How Dr. Bronner’s came to offer psychedelic therapy as a mental health benefit for employees

Family-owned soap company Dr. Bronner’s is offering a new health care benefit for its employees: ketamine-assisted therapy.

Since the company rolled out the policy in January, at least 30 employees have made use of the mental health benefit, which is about 10% of the company’s workforce, according to CEO David Bronner. 

Integration of psychedelic experiences linked to self-actualization via improvements in personal development and self-insight

New research suggests that improvements in personal development and self-insight act as a pathway between post-psychedelic integration practices and optimal well-being. The study, which appears in the Journal of Humanistic Psychology, provides evidence that this is the case for both clinical and non-clinical populations.

The psychedelic drugs lysergic acid diethylamide (LSD) and psilocybin (“magic mushrooms”) have shown promise in the treatment of psychiatric conditions, particularly when combined with supportive psychotherapy. Some preliminary research has also indicated that these substances can provide psychological benefits to non-clinical populations as well. The authors of the new study sought to better understand how psychedelic experiences may promote well-being.